AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25376930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch monotherapy
Number of subjects: 146
Study 25376930 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine transdermal patch therapy
Number of subjects: 146
Study 25376930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch or memantine add‐on therapy
Number of subjects: 146
Study 24195218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation (group T)
Number of subjects: 90
Study 24195218 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 21414183 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoinositol supplementation (4 g daily) plus folic acid (400 μg daily)
Number of subjects: 69
Study 21414183 — intervention group
Group type: COMPARATOR
Intervention: Folic acid only (400 μg daily)
Number of subjects: 69
Study 18640677 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 30
Study 18640677 — intervention group
Group type: COMPARATOR
Intervention: EGD
Number of subjects: 30
Study 17046467 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 900
Study 17046467 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 900
Study 17046467 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine
Number of subjects: 900
Study 17046467 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine plus sulphadoxine-pyrimethamine
Number of subjects: 900
Study 17046467 — intervention group
Group type: COMPARATOR
Intervention: No antimalarial drugs
Number of subjects: 900
Study 12670066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent matrices and reflective wedges
Number of subjects: 60
Study 12670066 — intervention group
Group type: COMPARATOR
Intervention: Metal matrices and wooden wedges
Number of subjects: 60
Study 12670066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid composite (Tetric) plus adhesive bonding agent (Syntac Classic)
Number of subjects: 60
Study 12670066 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite (Tetric Flow) plus Syntac Classic
Number of subjects: 60
Study 12670066 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract AP) plus adhesive bonding agent (Prime & Bond NT)
Number of subjects: 60
Study 11074747 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily enoxaparin
Number of subjects: 339
Study 11074747 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin
Number of subjects: 339
Study 11074747 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 339
Study 8753708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cephapirin sodium and gentamicin for three days
Number of subjects: 190
Study 8753708 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of ciprofloxacin for three days
Number of subjects: 190
Study 1415008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauric acid (C12:0)
Number of subjects: 14
Study 1415008 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid (C16:0)
Number of subjects: 14
Study 1415008 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (C18:1)
Number of subjects: 14
Study 3574639 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol 2 mg/day
Number of subjects: 107
Study 3574639 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol 1 mg/day
Number of subjects: 107
Study 3574639 — intervention group
Group type: COMPARATOR
Intervention: Flupentixol 0 mg/day (control)
Number of subjects: 107
Study 3574639 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol (0, 1, and 2 mg)
Number of subjects: 107
Study 29943163 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg for 8 weeks
Number of subjects: 139
Study 29943163 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg for 8 weeks
Number of subjects: 139
Study 29799875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-containing vaginal gel or insert
Number of subjects: 0
Study 29799875 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo products (vaginal gel or insert)
Number of subjects: 0
Study 29799875 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of semen
Number of subjects: 0
Study 26342054 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury (ESI)
Number of subjects: 154
Study 26342054 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) without ESI
Number of subjects: 154
Study 25040168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 30
Study 22745573 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 90
Study 22745573 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine iv bolus
Number of subjects: 90
Study 22745573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg iv paracetamol infusion
Number of subjects: 90
Study 20885427 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 22
Study 20885427 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 22
Study 17126520 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous treatment with expanded polytetrafluoroethylene (ePTFE)/nitinol self‐expanding stent grafts
Number of subjects: 100
Study 17126520 — intervention group
Group type: COMPARATOR
Intervention: Surgical femoral‐to‐above knee (AK) popliteal artery bypass with synthetic graft material
Number of subjects: 100
Study 15979790 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation (pressor pain) in Highs
Number of subjects: 18
Study 15979790 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation with instruction of analgesia in Highs
Number of subjects: 18
Study 15979790 — intervention group
Group type: COMPARATOR
Intervention: Painful stimulation (pressor pain) in Lows
Number of subjects: 18
Study 12765666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bengmark (spiral) nasojejunal tube
Number of subjects: 47
Study 12765666 — intervention group
Group type: COMPARATOR
Intervention: Medicina (straight) nasojejunal tube
Number of subjects: 47
Study 10320254 — intervention group
Group type: COMPARATOR
Intervention: Venoarterial pedicle preparation (group B)
Number of subjects: 112
Study 8532276 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual placental extraction
Number of subjects: 643
Study 8532276 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous placental delivery
Number of subjects: 643
Study 8532276 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove change plus manual extraction
Number of subjects: 643
Study 8532276 — intervention group
Group type: COMPARATOR
Intervention: Glove change plus spontaneous delivery
Number of subjects: 643
Study 1858987 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 1858987 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 30
Study 6343127 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel
Number of subjects: 31
Study 6343127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 31
Study 6343127 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study 31140663 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction to very low levels (n = 503)
Number of subjects: 1250
Study 31140663 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction (n = 498)
Number of subjects: 1250
Study 31140663 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes (n = 249)
Number of subjects: 1250
Study 30869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar incisor hypomineralization (MIH)
Number of subjects: 342
Study 30869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar hypomineralization (MH)
Number of subjects: 342
Study 30869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Demarcated opacities presence
Number of subjects: 342
Study 30869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of MIH
Number of subjects: 342
Study 25389213 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook™ advertisements (ads)
Number of subjects: 220
Study 25389213 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment methods
Number of subjects: 220
Study 25159623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast atazanavir clearance (≥9 L/h) in females
Number of subjects: 786
Study 25159623 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow atazanavir clearance (<7 L/h) in males
Number of subjects: 786
Study 25159623 — intervention group
Group type: COMPARATOR
Intervention: Middle atazanavir clearance (7 to <9 L/h)
Number of subjects: 786
Study 23121403 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 822
Study 23121403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 20368491 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted motivational intervention (CAMI) conducted quarterly with additional visits (CAMI+ [n = 80])
Number of subjects: 235
Study 20368491 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMI only (n = 87)
Number of subjects: 235
Study 20368491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 68)
Number of subjects: 235
Study 17428297 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 101
Study 17428297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 15212572 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group under time constraints
Number of subjects: 2
Study 15212572 — intervention group
Group type: COMPARATOR
Intervention: Control group performing at their own pace
Number of subjects: 2
Study 12324514 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaBoost classifier
Number of subjects: 386
Study 12324514 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted Decision Stump Feature Selection classifier
Number of subjects: 386
Study 9717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy for weeks 1 to 16
Number of subjects: 117
Study 9717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo with response prevention for weeks 1 to 16
Number of subjects: 117
Study 9717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine for weeks 1 to 16 plus cognitive therapy in weeks 9 to 16
Number of subjects: 117
Study 9717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine for weeks 1 to 16 plus exposure in vivo with response prevention in weeks 9 to 16
Number of subjects: 117
Study 9717867 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition for weeks 1 to 8
Number of subjects: 117
Study 7656956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen at 2 L.min‐1
Number of subjects: 12
Study 7656956 — intervention group
Group type: COMPARATOR
Intervention: Air cylinder walks (baseline)
Number of subjects: 12
Study 2663737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine 2 g intravenously
Number of subjects: 203
Study 2663737 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g intravenously
Number of subjects: 203
Study 205226 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix tablets (Digacin)
Number of subjects: 12
Study 205226 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix in capsule form
Number of subjects: 12
Study 205226 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix dragées
Number of subjects: 12
Study 205226 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix formulations (in vitro)
Number of subjects: 12
Study 205226 — intervention group
Group type: COMPARATOR
Intervention: conventional tablets from digoxin-lactose trituration (in vitro)
Number of subjects: 12
Study 30626313 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary patient‐centred team‐based intervention including self‐management support and a motivational approach
Number of subjects: 8
Study 30626313 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8
Study 28654304 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO) therapy
Number of subjects: 100
Study 28654304 — intervention group
Group type: COMPARATOR
Intervention: Sham device providing moist wound therapy (MWT)
Number of subjects: 100
Study 25453567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX), 2% CHX gel
Number of subjects: 30
Study 25453567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2/SSL, Ca(OH)2 + SSL
Number of subjects: 30
Study 25453567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2/CHX, Ca(OH)2 + 2% CHX gel
Number of subjects: 30
Study 23159021 — intervention group
Group type: EXPERIMENTAL
Intervention: VAMA(®) cannula
Number of subjects: 90
Study 23159021 — intervention group
Group type: COMPARATOR
Intervention: Berman(®) cannula
Number of subjects: 90
Study 23159021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VAMA(®) and Berman(®) cannulas
Number of subjects: 90
Study 21806906 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze dried powdered combination of Lactobacillus rhamnosus and Bifidobacterium species
Number of subjects: 150
Study 21806906 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze dried powdered preparation of Bacillus coagulans
Number of subjects: 150
Study 21806906 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 150
Study 19335153 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot technique (28F or 30F Amplatz dilator)
Number of subjects: 214
Study 19335153 — intervention group
Group type: COMPARATOR
Intervention: Alken telescopic dilators
Number of subjects: 214
Study 19335153 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot technique
Number of subjects: 214
Study 16780979 — intervention group
Group type: COMPARATOR
Intervention: Electron-beam irradiation at 0, 2, 4, 6, 8, and 10 kGy
Number of subjects: 4
Study 16780979 — intervention group
Group type: COMPARATOR
Intervention: Electron-beam irradiation at 8-10 kGy
Number of subjects: 4
Study 16780979 — intervention group
Group type: COMPARATOR
Intervention: Electron-beam irradiation at 6-10 kGy
Number of subjects: 4
Study 16780979 — intervention group
Group type: COMPARATOR
Intervention: Electron-beam irradiation
Number of subjects: 4
Study 16780979 — intervention group
Group type: COMPARATOR
Intervention: Electron-beam irradiation at 6-8 kGy
Number of subjects: 4
Study 14757608 — intervention group
Group type: EXPERIMENTAL
Intervention: WCV intervention (n = 3)
Number of subjects: 2843
Study 14757608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization intervention (n = 4)
Number of subjects: 2843
Study 14757608 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 2843
Study 11336156 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. over 5 days
Number of subjects: 12
Study 11336156 — intervention group
Group type: COMPARATOR
Intervention: Control (H. pylori‐negative)
Number of subjects: 12
Study 11336156 — intervention group
Group type: COMPARATOR
Intervention: Control (H. pylori‐positive)
Number of subjects: 12
Study 11336156 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 12
Study 9160036 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (S)
Number of subjects: 92
Study 9160036 — intervention group
Group type: EXPERIMENTAL
Intervention: Brow treatment (B)
Number of subjects: 92
Study 9160036 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner orbital treatment (IO)
Number of subjects: 92
Study 9160036 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer orbital treatment (OO)
Number of subjects: 92
Study 7968428 — intervention group
Group type: COMPARATOR
Intervention: Continuous warm-up (CW)
Number of subjects: 12
Study 7968428 — intervention group
Group type: COMPARATOR
Intervention: Interval warm-up (IW)
Number of subjects: 12
Study 7968428 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study 3317091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 17
Study 3317091 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 17
Study 31373696 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered glucocorticosteroids preoperatively
Number of subjects: 52
Study 31373696 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) without preoperative steroids
Number of subjects: 52
Study 31373696 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative olfactory dynamics after ESS
Number of subjects: 52
Study 31217344 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + letrozole (palbociclib: 125 mg daily; 3 weeks on/1 week off; letrozole: 2.5 mg daily continuously)
Number of subjects: 666
Study 31217344 — intervention group
Group type: COMPARATOR
Intervention: Placebo + letrozole (letrozole: 2.5 mg daily continuously)
Number of subjects: 666
Study 27979064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (0.5%, 1.0%, 1.5%)
Number of subjects: 40
Study 27979064 — intervention group
Group type: COMPARATOR
Intervention: Control (2.5% sunflower oil)
Number of subjects: 40
Study 25103680 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) aiming at peak Edi between 5 and 15 µV
Number of subjects: 81
Study 25103680 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 81
Study 23314589 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise (CSE)
Number of subjects: 46
Study 23314589 — intervention group
Group type: COMPARATOR
Intervention: Spinal Flexibility Exercise (SFE)
Number of subjects: 46
Study 21942614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 63
Study 21942614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 18644124 — intervention group
Group type: EXPERIMENTAL
Intervention: MonoMax suture material
Number of subjects: 150
Study 18644124 — intervention group
Group type: COMPARATOR
Intervention: Monoplus and PDS (historical control)
Number of subjects: 150
Study 16391574 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day diet record (7-DDR)
Number of subjects: 65
Study 16391574 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire (FFQ)
Number of subjects: 65
Study 14704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.05 mg/d) plus progestin (2.5 mg/d; n = 31)
Number of subjects: 82
Study 14704262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/d) plus progestin (2.5 mg/d; n = 30)
Number of subjects: 82
Study 14704262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 82
Study 11412219 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity (one concomitant disease)
Number of subjects: 894
Study 11412219 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity (two or more diseases)
Number of subjects: 894
Study 11412219 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor differentiation of the tumour
Number of subjects: 894
Study 9220037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 91
Study 9220037 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine coat-core (CC)
Number of subjects: 91
Study 8432777 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 25% fat and 60% carbohydrate (CHO)
Number of subjects: 8
Study 8432777 — intervention group
Group type: COMPARATOR
Intervention: Diet with 40% fat and 45% carbohydrate (CHO)
Number of subjects: 8
Study 2951031 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (40 micrograms X kg‐1)
Number of subjects: 36
Study 2951031 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms X kg‐1)
Number of subjects: 36
Study 29234884 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy combined with steroid injection (Group 1)
Number of subjects: 44
Study 29234884 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection (Group 2)
Number of subjects: 44
Study 26909885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Advance 10 mL four times a day
Number of subjects: 136
Study 26909885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 24982236 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with DFX 30 mg/kg
Number of subjects: 8
Study 24982236 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with DFP 80 mg/kg/day
Number of subjects: 8
Study 24982236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with DFX 30 mg/kg and DFP 40 mg/kg
Number of subjects: 8
Study 24982236 — intervention group
Group type: COMPARATOR
Intervention: Concurrent therapy with DFX 30 mg/kg and DFP 80 mg/kg
Number of subjects: 8
Study 22156009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection (C: 6 mL/s; D: 8 mL/s)
Number of subjects: 180
Study 22156009 — intervention group
Group type: COMPARATOR
Intervention: Unilateral injection (A: 4 mL/s; B: 6 mL/s)
Number of subjects: 180
Study 20728299 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic support program for new B-MAT patients
Number of subjects: 0
Study 20728299 — intervention group
Group type: EXPERIMENTAL
Intervention: B-MAT (buprenorphine medication-assisted treatment)
Number of subjects: 0
Study 19167585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled insulin delivery device (NovoMix 30 FlexPen)
Number of subjects: 61
Study 19167585 — intervention group
Group type: COMPARATOR
Intervention: Reusable insulin delivery device (HumaPen Luxura)
Number of subjects: 61
Study 19167585 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference for devices
Number of subjects: 61
Study 19167585 — intervention group
Group type: COMPARATOR
Intervention: Injection time excluding cartridge insertion for HL device
Number of subjects: 61
Study 11174477 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol plus sequential norethindrone acetate
Number of subjects: 16